Risk of second cancer in patients with hairy cell leukemia

Long-term follow-up

Massimo Federico, Pier Luigi Zinzani, Antonio Frassoldati, Marco Vinceti, Alessia Modè, Luciana Annino, Teodoro Chisesi, Guido Pagnucco, Rosangela Invernizzi, Mauro Spriano, Luigi Resegotti, Maurizio Bendandi, Eugenio E. Damasio

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and Methods: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. Results: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin's lymphoma in the entire cohort was 5.3 (95% CI, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. Conclusion: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.

Original languageEnglish
Pages (from-to)638-646
Number of pages9
JournalJournal of Clinical Oncology
Volume20
Issue number3
DOIs
Publication statusPublished - Feb 1 2002

Fingerprint

Hairy Cell Leukemia
Second Primary Neoplasms
Interferons
Incidence
Confidence Intervals
Information Centers
Skin Neoplasms
Non-Hodgkin's Lymphoma
Registries
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Federico, M., Luigi Zinzani, P., Frassoldati, A., Vinceti, M., Modè, A., Annino, L., ... Damasio, E. E. (2002). Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up. Journal of Clinical Oncology, 20(3), 638-646. https://doi.org/10.1200/JCO.20.3.638

Risk of second cancer in patients with hairy cell leukemia : Long-term follow-up. / Federico, Massimo; Luigi Zinzani, Pier; Frassoldati, Antonio; Vinceti, Marco; Modè, Alessia; Annino, Luciana; Chisesi, Teodoro; Pagnucco, Guido; Invernizzi, Rosangela; Spriano, Mauro; Resegotti, Luigi; Bendandi, Maurizio; Damasio, Eugenio E.

In: Journal of Clinical Oncology, Vol. 20, No. 3, 01.02.2002, p. 638-646.

Research output: Contribution to journalArticle

Federico, M, Luigi Zinzani, P, Frassoldati, A, Vinceti, M, Modè, A, Annino, L, Chisesi, T, Pagnucco, G, Invernizzi, R, Spriano, M, Resegotti, L, Bendandi, M & Damasio, EE 2002, 'Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up', Journal of Clinical Oncology, vol. 20, no. 3, pp. 638-646. https://doi.org/10.1200/JCO.20.3.638
Federico M, Luigi Zinzani P, Frassoldati A, Vinceti M, Modè A, Annino L et al. Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up. Journal of Clinical Oncology. 2002 Feb 1;20(3):638-646. https://doi.org/10.1200/JCO.20.3.638
Federico, Massimo ; Luigi Zinzani, Pier ; Frassoldati, Antonio ; Vinceti, Marco ; Modè, Alessia ; Annino, Luciana ; Chisesi, Teodoro ; Pagnucco, Guido ; Invernizzi, Rosangela ; Spriano, Mauro ; Resegotti, Luigi ; Bendandi, Maurizio ; Damasio, Eugenio E. / Risk of second cancer in patients with hairy cell leukemia : Long-term follow-up. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 3. pp. 638-646.
@article{6ff7e76020e1487baeb87b2c0c12a747,
title = "Risk of second cancer in patients with hairy cell leukemia: Long-term follow-up",
abstract = "Purpose: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and Methods: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. Results: The cumulative risk of development of a second cancer was 5{\%}, 10{\%}, and 14{\%} at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95{\%} confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin's lymphoma in the entire cohort was 5.3 (95{\%} CI, 1.9 to 11.5). Second malignancies occurred in eight (4.7{\%}) of 386 patients who never received interferon (IFN), nine (5.9{\%}) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9{\%}) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. Conclusion: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.",
author = "Massimo Federico and {Luigi Zinzani}, Pier and Antonio Frassoldati and Marco Vinceti and Alessia Mod{\`e} and Luciana Annino and Teodoro Chisesi and Guido Pagnucco and Rosangela Invernizzi and Mauro Spriano and Luigi Resegotti and Maurizio Bendandi and Damasio, {Eugenio E.}",
year = "2002",
month = "2",
day = "1",
doi = "10.1200/JCO.20.3.638",
language = "English",
volume = "20",
pages = "638--646",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Risk of second cancer in patients with hairy cell leukemia

T2 - Long-term follow-up

AU - Federico, Massimo

AU - Luigi Zinzani, Pier

AU - Frassoldati, Antonio

AU - Vinceti, Marco

AU - Modè, Alessia

AU - Annino, Luciana

AU - Chisesi, Teodoro

AU - Pagnucco, Guido

AU - Invernizzi, Rosangela

AU - Spriano, Mauro

AU - Resegotti, Luigi

AU - Bendandi, Maurizio

AU - Damasio, Eugenio E.

PY - 2002/2/1

Y1 - 2002/2/1

N2 - Purpose: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and Methods: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. Results: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin's lymphoma in the entire cohort was 5.3 (95% CI, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. Conclusion: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.

AB - Purpose: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). Patients and Methods: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. Results: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin's lymphoma in the entire cohort was 5.3 (95% CI, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. Conclusion: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.

UR - http://www.scopus.com/inward/record.url?scp=0036467659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036467659&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.3.638

DO - 10.1200/JCO.20.3.638

M3 - Article

VL - 20

SP - 638

EP - 646

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -